Buprenorphine/naloxone
| Combination of | |
|---|---|
| Buprenorphine | Opioid modulator |
| Naloxone | Opioid antagonist |
| Clinical data | |
| Trade names | Suboxone |
| Legal status |
|
| Routes of administration | Sublingual |
Suboxone.
Buprenorphine/naloxone (brand name Suboxone) is a combination drug formulation of buprenorphine, a μ-opioid receptor (MOR) weak partial agonist and κ-opioid receptor antagonist, and naloxone, a MOR silent antagonist, in a 4:1 ratio.[1][2] It is used in the treatment of opioid dependence.[1][2] The purpose of naloxone is to deter intravenous abuse; parenteral administration rapidly induces opioid withdrawal symptoms, while regular, intended use does not (as naloxone is minimally bioavailable with sublingual ingestion).[1][2][3][4] In spite of the fact that the drug is intended to treat opioid dependence, it is still addictive.[1]
See also
References
- 1 2 3 4 Diane S. Aschenbrenner; Samantha J. Venable (2009). Drug Therapy in Nursing. Lippincott Williams & Wilkins. pp. 396–. ISBN 978-0-7817-6587-9.
- 1 2 3 Gary L. Fisher; Nancy A. Roget (11 November 2008). Encyclopedia of Substance Abuse Prevention, Treatment, and Recovery. SAGE Publications. pp. 570–. ISBN 978-1-4129-5084-8.
- ↑ Atta-ur Rahman; M. Iqbal Choudhary (1 January 2010). Frontiers in CNS Drug Discovery. Bentham Science Publishers. pp. 631–. ISBN 978-1-60805-159-5.
- ↑ Linda E. McCuistion; Joyce LeFever Kee; Evelyn R. Hayes (25 March 2014). Pharmacology: A Patient-Centered Nursing Process Approach. Elsevier Health Sciences. pp. 56–. ISBN 978-0-323-29348-8.
| ||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Monday, February 01, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.